U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


U.S. Issues Cuba Health Alert as Illnesses Rise
Iran Plans New Gulf Restricted Zone as Hormuz Tensions Push Oil Higher
Trump Grants Clemency to Jay-Z Associate Emory Jones
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
EU to Boost Greenland Investment Amid Trump Pressure
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal
Trump Signs Order to Cut Routine Childhood Vaccines
Trump Seeks Europe Repayment for U.S. Ukraine Military Aid
Lavrov Accuses Germany of ‘Declaring War’ on Russia
Putin Meets US Envoys in Moscow as Ukraine Peace Push Intensifies
Japan, US Target AI and Chips in $550 Billion Investment Push
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



